NYU Langone’s Seligman Center for Advanced Therapeutics was established in 2003 through the support of a grateful patient who wanted to connect other patients with clinical trials that would give them access to the latest treatments for rheumatic conditions.
The Seligman Center patient registry now has data on nearly 9,000 patients. Our clinical trials focus on the following diseases and conditions: osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, dermatomyositis, seronegative arthritis, fibromyalgia, osteoporosis, Behcet’s syndrome, vasculitis, scleroderma, gout, familial Mediterranean fever, ankylosing spondylitis, Paget’s disease, systemic lupus erythematosus, Sjogren’s syndrome, antiphospholipid syndrome, and mixed connective tissue disorder.
The Seligman Center is a key site for numerous nationally conducted clinical studies, trials, and registries, and is staffed by physicians with unique expertise in rheumatic diseases. Our doctors are directly involved in the development of protocols for testing the effectiveness and safety of cutting-edge investigational therapies.
Approximately 25 clinical trials are currently underway, including the Psoriatic Arthritis Translational Registry and Biorepository, one of the largest psoriasis and psoriatic arthritis patient registries in the country. The registry, established in 2005, oversees the collection of long-term clinical data and biospecimens that can help predict patient response to new therapies.
This research is a prime resource for investigators working with biotechnology and pharmaceutical companies on new medication therapies. We also conduct research into Behcet’s syndrome, in collaboration with the National Institutes of Health.